“We interacted with ChatGPT much like a colleague, asking it to synthesize, simplify and offer counterpoints,” the researchers wrote.
The results from Katcher’s latest study will be written up when Sima dies, but data gathered so far suggests that eight rats that received placebo infusions of saline lived for 34 to 38 months, while eight that received a purified and concentrated form of blood plasma, called E5, lived for 38 to 47 months. They also had improved grip strength. Rats normally live for two to three years, though a contender for the oldest ever is a brown rat that survived on a restricted calorie diet for 4.6 years.
“The real point of our experiments is not so much to extend lifespan, but to extend youthspan, to rejuvenate people, to make their golden years really potentially golden years, instead of years of pain and decrepitude,” Katcher said. “But the fact is, if you manage to do that, you also manage to lengthen life and that’s not a bad side-effect.”
Results from such small studies are tentative at best, but some scientists believe the work, and similar efforts by others, has potential. A preliminary study from a collaboration between Katcher and experts at the University of California in Los Angeles found that infusions of young blood plasma wound back the biological clock on rat liver, blood, heart and a brain region called the hypothalamus. Commenting on the work in 2020, Prof David Sinclair, a leading expert on ageing at Harvard medical school, said if the finding held up, “rejuvenation of the body may become commonplace within our lifetimes”.
EXCLUSIVE: Clones are the next step in extending human life, scientist believes The technique has proved successful in animals but not yet worked in people Dr Alex Zhavoronkov believes it will offer ‘spare’ organs for people as they age Regardless of the huge strides scientists have made towards reaching the elusive goal, immortality remains a pipedream.
Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have poorer outcomes compared to other breast cancers, suggesting the need for improved treatments. One new therapy being investigated at Moffitt Cancer Center involves oncolytic viruses, which infect and kill the cancer cells. In a new article published in Nature Medicine, the researchers, led by Hatem Soliman, M.D., share results from a phase 2 clinical trial of the oncolytic virus talimogene laherparepvec (TVEC) combined with standard chemotherapy in patients with early stage triple-negative breast cancer.
Patients with triple-negative breast cancer lack expression of the estrogen and progesterone receptors and have little to no expression of the protein HER2. As a result, hormone therapy and medicines that target HER2 protein receptors are not effective against this type of cancer. Standard therapy for early stage triple-negative breast cancer has been cytotoxic chemotherapy with the recent addition of pembrolizumab. However, this approach is associated with significant side effects. Many studies have shown that patients who have higher levels of immune cells within their tumors tend to have better responses to therapy. These observations suggest that agents that stimulate the immune system may be beneficial in triple-negative breast cancer.
TVEC is a modified herpes simplex 1 virus that includes coding sequences for the protein GM-CSF, which can stimulate the immune system. It is injected directly into the tumor and undergoes replication within the tumor cells, resulting in the breakdown of the tumor cell and production of tumor derived antigens. Immune cells can recognize the antigens, infiltrate the tumor and target the cancer cells for destruction. In addition, GM-CSF made by the virus acts as a beacon to help recruit immune cells to the tumor.
Scientists have developed a molecular compound that’s so effective in killing off disease-causing fungi that it’s been named after Keanu Reeves. The people of Hollywood may as well pack up and finish awards season early this year, because nothing is going to beat this honour. From The Matrix to John Wick, Keanu Reeves has shown us time and time again how much of a badass he is, and now the science world is ready to recognise him for it.
Innovative treatment designed to treat mitochondrial disease shows promise in a few patients.
Injury to the spinal cord often leads life changing disability, with decreased or complete loss of sensation and movement below the site of injury. From drugs to transplantation, there are many scientific advances aiming to restore function following spinal cord injury.
One promising approach is the use of stem cell derived neurons to replace those damaged. New research from the Centre for Gene Therapy & Regenerative Medicine and Centre for Neurodevelopment at King’s College London hopes to improve on this approach by providing pure populations of neurons made from stem cells.
The spinal cord is a delicate structure, with neurons carry messages from your brain to the rest of your body to allow movement and sensation. Integral to this system are interneurons, or the cells that relay information between your brain and other neurons. Research has previously shown that transplanting a class of interneurons, ventral spinal interneurons, to treat spinal cord injury in animal models provides promising recovery of sensory and motor function.
The immune system can mount crucial defenses when our bodies are threatened by pathogens. But those defenses have to be carefully contained. When processes in the human system go awry, serious diseases can result. Now scientists have learn more about how connective tissue works to control inflammatory molecules so they can act locally but don’t spread throughout the body. The findings have been reported in Nature Immunology.
Cytokines are immune signaling molecules, and they help T cells communicate. Interferon-gamma is one cytokine that plays a critical role in the elimination of bacterial and viral invaders. Scientists have discoverd that this molecule uses a sequence of four amino acids to bind to the extracellular matrix that connects cells and mediates interactions between them. Interferon-gamma gets caught in that connective tissue, and cannot spread to other areas.
With a big assist from artificial intelligence and a heavy dose of human touch, Tim Cernak’s lab at the University of Michigan has made a discovery that dramatically speeds up the time-consuming chemical process of building molecules that will be tomorrow’s medicines, agrichemicals or materials.
The discovery, published in the Feb. 3 issue of Science, is the culmination of years of chemical synthesis and data science research by the Cernak Lab in the College of Pharmacy and Department of Chemistry.
The goal of the research was to identify key reactions in the synthesis of a molecule, ultimately reducing the process to as few steps as possible. In the end, Cernak and his team achieved the synthesis of a complex alkaloid found in nature in just three steps. Previous syntheses had taken between seven and 26 steps.
